N@N

Jay Olson Reiterated (BIIB) at Buy and Held Target at $295 on, Jan 30th, 2024

Jay Olson of Oppenheimer, Reiterated "Biogen Inc." (BIIB) at Buy and Held Target at $295 on, Jan 30th, 2024.

Jay has made no other calls on BIIB in the last 4 months.

There are 10 other peers that have a rating on BIIB. Out of the 10 peers that are also analyzing BIIB, 2 agree with Jay's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Colin Bristow of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $276 on, Thursday, January 25th, 2024
• Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $239 on, Thursday, November 9th, 2023

These are the ratings of the 8 analyists that currently disagree with Jay

---

• Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $311 on, Wednesday, December 20th, 2023
• Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $287 on, Thursday, December 14th, 2023
• Danielle Brill of "Raymond James" Upgraded from Hold to Buy and Held Target at $283 on, Thursday, December 7th, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $373 on, Friday, November 10th, 2023
• Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $365 on, Thursday, November 9th, 2023
• Evan Seigerman of "BMO Capital" Maintained at Buy with Decreased Target to $295 on, Thursday, November 9th, 2023
• Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $363 on, Thursday, November 9th, 2023
• Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $305 on, Thursday, October 26th, 2023

Contributing Sources

---